Search
                    Follicular Lymphoma Clinical Trials
A listing of 62  Follicular Lymphoma  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 62
        
                There are currently 62 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Follicular Lymphoma participants are Texas, California, New York and Florida.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
                                
            
            
        Recruiting
                            
            
                The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.
Primary Objectives
• To determ...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 0 years and 38 years
            Trial Updated:
                07/02/2025
            
            Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio         
        
        
            Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
        
            
        
    
                
                                    A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)
                                
            
            
        Recruiting
                            
            
                The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/21/2025
            
            Locations: Local Institution - 0225, Birmingham, Alabama  +153 locations         
        
        
            Conditions: Follicular Lymphoma
        
            
        
    
                
                                    A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
                                
            
            
        Recruiting
                            
            
                Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/19/2025
            
            Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama  +116 locations         
        
        
            Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
        
            
        
    
                
                                    Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
                                
            
            
        Recruiting
                            
            
                The researchers are doing this study to measure and test cell-free DNA (cfDNA) in the blood before, during, and after first-line treatment for follicular lymphoma. They will look at whether cfDNA levels are related to a person's response to the usual first-line treatment for follicular lymphoma. Researchers also want to understand how different genetic changes in follicular lymphoma relate to a person's response to the usual first-line treatment.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/18/2025
            
            Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey  +6 locations         
        
        
            Conditions: Follicular Lymphoma
        
            
        
    
                
                                    SynKIR-310 for Relapsed/Refractory B-NHL
                                
            
            
        Recruiting
                            
            
                This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/18/2025
            
            Locations: Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver, Colorado  +3 locations         
        
        
            Conditions: B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Aggressive B-Cell Non-Hodgkin Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, HGBL with MYC and BCL2 And/or BCL6 Rearrangements, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, Non-hodgkin Lymphoma,B Cell, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Epstein-Barr Virus Positive DLBCL, Nos, Follicular Lymphoma Grade 3B, DLBCL (Diffuse Large B-Cell Lymphoma) Associated with Chronic Inflammation, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Lymphoma Grade 3, Marginal Zone Splenic Lymphoma, DLBCL
        
            
        
    
                
                                    A Long-term Extension Study of PCI-32765 (Ibrutinib)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/15/2025
            
            Locations: City of Hope Cancer Center, Duarte, California  +173 locations         
        
        
            Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
        
            
        
    
                
                                    A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
                                
            
            
        Recruiting
                            
            
                This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 130 years
            Trial Updated:
                08/14/2025
            
            Locations: Research Site, Tampa, Florida  +26 locations         
        
        
            Conditions: B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
        
            
        
    
                
                                    A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
                                
            
            
        Recruiting
                            
            
                This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York         
        
        
            Conditions: Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
        
            
        
    
                
                                    A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate.
* Cohort A: Participants with relapsed or refractory MCL r...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska  +108 locations         
        
        
            Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
        
            
        
    
                
                                    A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Georgetown University (Data Collection Only), Washington, District of Columbia  +8 locations         
        
        
            Conditions: Follicular Lymphoma, Lymphoma
        
            
        
    
                
                                    Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
                                
            
            
        Recruiting
                            
            
                This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment.
The name of the study drug in this research study is:
-Epcoritamab (a type of antibody)             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts         
        
        
            Conditions: Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
        
            
        
    
                
                                    Clonal Evolution in Follicular Lymphoma
                                
            
            
        Recruiting
                            
            
                Background:
Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments.
Objective:
To collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment.
Eligibili...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/13/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Follicular Lymphoma
        
            
        
    1 - 12 of 62
            